Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.
Taylor MorrisetteSara AlosaimyAbdalhamid M LagnfJeremy J FrensAndrew J WebbMichael P VeveRyan StevensJeannette BouchardTristan W GoreIman AnsariMichael J RybakPublished in: Infectious diseases and therapy (2022)
The use of oral OMC in MDR/XDR Gram-negative infections exhibited a relatively high success rate with minimal adverse effects. Real-world studies with larger case numbers are needed to confirm our initial findings.